Skip to main content
SpringerLink
Log in

Lymphomes et autres tumeurs hématologiques

  • Chapter
Book cover Cancer du sujet âgé

Part of the book series: Oncologie pratique ((ONCOLPRAT))

Abstrait

Le vieillissement de la population, l’augmentation de l’incidence des cancers avec l’âge et, enfin, l’augmentation d’incidence des lymphomes au cours des dernières années sont autant de raisons qui nous imposent de porter nos efforts pour améliorer la prise en charge des personnes âgé es dans l’avenir.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Remontet L, Estève J, Bouvier A-M et al. (2003) Cancer incidence and mortality in France over the period 1978–2000. Rev Epidémiol Santé Publ 51: 3–30

    CAS  Google Scholar 

  2. Black RJ, Bray F, Ferlay J, Parkin DM (1997) Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33: 1075–107

    Article  PubMed  CAS  Google Scholar 

  3. Devesa SS, Fears T (1992) Non-Hodgkin’s lymphoma time trends: United States and international data. Cancer Res 52: 5432s–40s

    PubMed  CAS  Google Scholar 

  4. Rollandportal I, Tazi MA, Milan C, Couillault C et al. (1997) Non-Hodgkin’s lymphoma: Time trends for incidence and survival in Cote-D’Or, France. Int J Epidemiol 26:945–52

    Article  CAS  Google Scholar 

  5. Cartwright R, Brincker H, Carli PM et al. (1999) The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 35: 627–33

    Article  PubMed  CAS  Google Scholar 

  6. Groves FD, Linet MS, Travis LB, Devesa SS (2000) Cancer surveillance series: Non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Nat Cancer Inst 92: 1240–51

    Article  PubMed  CAS  Google Scholar 

  7. Carli PM, Boutron MC, Maynadie M et al. (1994) Increase in the incidence of non-Hodgkin’s lymphomas: evidence for a recent sharp increase in France independent of AIDS. Br J Cancer 70: 713–5

    PubMed  CAS  Google Scholar 

  8. Morgan G, Vornanen M, Puitinen J et al. (1997) Changing trends in the incidence of non-Hodgkin’s lymphoma in Europe. Ann Oncol 8: 49–54

    Article  PubMed  Google Scholar 

  9. Morton et al. (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107: 265–76

    Article  PubMed  CAS  Google Scholar 

  10. Cartwright RA, Gilman EA, Gurney KA (1999) Time trends in incidence of haematological malignancies and related conditions. Br J Haematol 106: 281–95

    Article  PubMed  CAS  Google Scholar 

  11. Maynadie M, Verret C, Moskovtchenko P et al. (1996) Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer 74: 288–90

    PubMed  CAS  Google Scholar 

  12. Carli PM, Coebergh JWW, Verdecchia A (1998) Variation in survival of adult patients with haematological malignancies in Europe since 1978. Eur J Cancer 34: 2253–63

    Article  CAS  Google Scholar 

  13. Vercelli M, Quaglia A, Casella C et al. (1998) Relative survival in elderly cancer patients in Europe. EUROCARE Working Group. Eur J Cancer 34: 2264–70

    Article  CAS  Google Scholar 

  14. Harris NL, Jaffe ES, Diebold J et al. (1999) World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-airlie house, Virginia, November 1997. J Clin Oncol 17: 3835–49

    PubMed  CAS  Google Scholar 

  15. Extermann M, Overcash J, Lyman GH et al. (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16: 1582–7

    PubMed  CAS  Google Scholar 

  16. Monfardini S, Balducci L (1999) A comprehensive geriatric assessment (CGA) is necessary for the study and the management of cancer in the elderly. Eur J Cancer 35: 1771–2

    Article  PubMed  CAS  Google Scholar 

  17. Carbone PP, Kaplan HS, Musshoff K et al. (1971) Report of the Comittee of Hodgkin’s disease staging classification. Cancer Res 31: 1860–1

    PubMed  CAS  Google Scholar 

  18. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329: 987–94

    Article  Google Scholar 

  19. Foussard C, Desablens B, Sensebe L et al. (1997) Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage IIIIV patients. Ann Oncol 8: 49–52

    Article  PubMed  Google Scholar 

  20. Hermans J, Krol ADG, Vangroningen K et al. (1995) International prognostic index for aggressive non-Hodgkin’s lymphoma is valid for all malignancy grades. Blood 86: 1460–3

    PubMed  CAS  Google Scholar 

  21. Solal-Céligny P, Roy P, Colombat P et al. (2004) Follicular Lymphoma International Prognostic Index. Blood 104: 1258–65

    Article  PubMed  CAS  Google Scholar 

  22. Cheson BD, Horning SJ, Coiffier B et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17: 1244–53

    PubMed  CAS  Google Scholar 

  23. Juweid ME, Wiseman GA, Vose JM et al. (2005) Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 20;23(21): 4652–61

    Article  Google Scholar 

  24. Hoerni B, Sotto JJ, Eghbali H et al. (1988) Non-Hodgkin’s malignant lymphomas in patients older than 80. 70 cases. Cancer 61: 2057–9

    Article  PubMed  CAS  Google Scholar 

  25. Maartense E, Hermans J, Kluinnelemans JC et al. (1998) Elderly patients with non-Hodgkin’s lymphoma: Population-based results in the Netherlands. Ann Oncol 9: 1219–27

    Article  PubMed  CAS  Google Scholar 

  26. Chan WC, Armitage JO, Gascoyne R et al. (1997) Effect of age on the characteristics and clinical behavior of non-Hodgkin’s lymphoma patients. Ann Oncol 8: 973–8

    Article  Google Scholar 

  27. D’Amore F, Brincker H, Christensen BE et al. (1992) Non-Hodgkin’s lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. Ann Oncol 3: 379–86

    PubMed  CAS  Google Scholar 

  28. Weiss LM, Warnke RA, Sklar J, Cleary ML (1987) Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 317: 1185–9

    Article  PubMed  CAS  Google Scholar 

  29. Armitage JO, Weisenburger DD (1998) New approach to classifying non-hodgkin’s lymphomas: Clinical features of the major histologic subtypes. J Clin Oncol 16: 2780–95

    PubMed  CAS  Google Scholar 

  30. Hoerni B (1985) Follicular lymphomas. J Eur Radiother 6: 121–8

    Google Scholar 

  31. Bastion Y, Berger F, Bryon PA et al. (1991) Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 2Suppl 2: 123–9

    PubMed  Google Scholar 

  32. Soubeyran P, Eghbali H, Bonichon F et al. (1991) Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients. Eur J Cancer 27: 1606–13

    Article  PubMed  CAS  Google Scholar 

  33. Horning SJ (1993) Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 20: 75–88

    PubMed  CAS  Google Scholar 

  34. Coiffier B, Bastion Y, Berger F et al. (1993) Prognostic factors in follicular lymphomas. Semin Oncol 20: 89–95

    PubMed  CAS  Google Scholar 

  35. Soubeyran P, Brousse N, Costa A et al. (1999) Follicular lymphoma registry in France. Ann Oncol 10(Suppl. 3): 117

    Google Scholar 

  36. Macmanus MP, Hoppe RT (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14: 1282–90

    CAS  Google Scholar 

  37. Paryani SB, Hoppe RT, Cox RS et al. (1983) Analysis of non-Hodgkin’s lymphomas with nodular and favorable histologies, stages I and II. Cancer 52: 2300–7

    Article  PubMed  CAS  Google Scholar 

  38. Soubeyran P, Eghbali H, Bonichon F et al. (1988) Localized follicular lymphomas: prognosis and survival of stages I and II in a retrospective series of 103 patients. Radiother Oncol 13: 91–8

    Article  PubMed  CAS  Google Scholar 

  39. Landberg TG, Hakansson LG, Moller TR et al. (1979) CVP-remission-maintenance in stage I or II non-Hodgkin’s lymphomas: preliminary results of a randomized study. Cancer 44: 831–8

    Article  PubMed  CAS  Google Scholar 

  40. Monfardini S, Banfi A, Bonadonna G et al. (1980) Improved five year survival after combined radiotherapy-chemotherapy for stage I–II non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 6: 125–34

    PubMed  CAS  Google Scholar 

  41. Nissen NI, Ersboll J, Hansen HS et al. (1983) A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I–II non-Hodgkin’s lymphomas. Cancer 52: 1–7

    Article  PubMed  CAS  Google Scholar 

  42. Soubeyran P, Eghbali H, Trojani M et al. (1996) Is there any place for a wait-and-see policy in stage I-0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol 7: 713–8

    PubMed  CAS  Google Scholar 

  43. Seymour JF, McLaughlin P, Fuller LM et al. (1996) High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol 7: 157–63

    PubMed  CAS  Google Scholar 

  44. Ardeshna KM, Smith P, Norton A et al. (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet 362: 516–522

    Article  PubMed  CAS  Google Scholar 

  45. Ezdinli EZ, Anderson JR, Melvin F et al. (1985) Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 3: 769–75

    PubMed  CAS  Google Scholar 

  46. Kimby E, Bjorkholm M, Gahrton G et al. (1994) Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin’s lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 5(Suppl. 2): 67–71

    PubMed  Google Scholar 

  47. Lepage E, Sebban C, Gisselbrecht C et al. (1990) Treatment of low-grade non-Hodgkin’s lymphomas: assessment of doxorubicin in a controlled trial. Hematol Oncol 8: 31–9

    Article  PubMed  CAS  Google Scholar 

  48. Lister TA, Cullen MH, Beard ME et al. (1978) Comparison of combined and single-agent chemotherapy in non-Hodgkin’s lymphoma of favourable histological type. Br Med J 1: 533–7

    Article  PubMed  CAS  Google Scholar 

  49. Meerwaldt JH, Carde P, Burgers JM et al. (1991) Low-dose total body irradiation versus combination chemotherapy for lymphomas with follicular growth pattern. Int J Radiat Oncol Biol Phys 21: 1167–72

    PubMed  CAS  Google Scholar 

  50. Portlock CS, Rosenberg SA, Glatstein E, Kaplan HS (1976) Treatment of advanced non-Hodgkin’s lymphomas with favorable histologies: preliminary results of a prospective trial. Blood 47: 747–56

    PubMed  CAS  Google Scholar 

  51. Rosenberg SA. Karnofsky memorial lecture (1985) The low-grade non-Hodgkin’s lymphomas: challenges and opportunities. J Clin Oncol 3: 299–310

    PubMed  CAS  Google Scholar 

  52. Steward WP, Crowther D, McWilliam LJ et al. (1988) Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin’s lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 61: 441–7

    Article  PubMed  CAS  Google Scholar 

  53. Young RC, Longo DL, Glatstein E et al. (1988) The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 25: 11–6

    PubMed  CAS  Google Scholar 

  54. Hagenbeek A, Carde P, Meerwaldt JH et al. (1998) Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin’s lymphoma. J Clin Oncol 16: 41–7

    PubMed  CAS  Google Scholar 

  55. Chisesi T, Congiu M, Contu A et al. (1991) Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin’s lymphoma: an interim report of a randomized study. Non-Hodgkin’s Lymphoma Cooperative Study Group. Eur J Cancer 27(Suppl. 4): S31–3

    PubMed  Google Scholar 

  56. Smalley RV, Andersen JW, Hawkins MJ et al. (1992) Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin’s lymphoma. N Engl J Med 327: 1336–41

    Article  PubMed  CAS  Google Scholar 

  57. Solal-Celigny P, Lepage E, Brousse N et al. (1998) Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 trial. J Clin Oncol 16: 2332–8

    PubMed  CAS  Google Scholar 

  58. Rohatiner AZ, Gregory WM, Peterson B et al. (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23: 2215–23

    Article  PubMed  CAS  Google Scholar 

  59. Brice P, mnSolal Celigny P, Lepage E et al. (1995) A randomized study in low tumor burden follicular lymphoma between no treatment, prednimustine and interferon. J Clin Oncol 14: 394-

    Google Scholar 

  60. McLaughlin P, Hagemeister FB, Romaguera JE et al. (1996) Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 14: 1262–8

    PubMed  CAS  Google Scholar 

  61. Zinzani PL, Magagnoli M, Bendandi M et al. (2000) Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin’s lymphomas. Ann Oncol 11: 363–5

    Article  PubMed  CAS  Google Scholar 

  62. Hochster HS, Oken MM, Winter JN et al. (2000) Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results and long-term follow-up-A report from the Eastern Cooperative Oncology Group. J Clin Oncol 18: 987–94

    PubMed  CAS  Google Scholar 

  63. Soubeyran P, Monnereau A, Eghbali H et al. (2005) Fludarabine Phosphate-CVP in Patients Over 60 Years of Age with Advanced, Low-Grade and Follicular Lymphoma: A Dose-Finding Study. Eur J Cancer 41: 2630–6

    Article  PubMed  CAS  Google Scholar 

  64. Maloney DG, Grillolopez AJ, White CA et al. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90: 2188–95

    PubMed  CAS  Google Scholar 

  65. McLaughlin P, Grillolopez AJ, Link BK et al. (1998) Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825–33

    PubMed  CAS  Google Scholar 

  66. Hainsworth JD, Burris HA, Morrissey LH et al. (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95: 3052–6, 2000.

    PubMed  CAS  Google Scholar 

  67. Colombat P, Salles G, Brousse N et al. (2001) Rituximab (anti CD20 monoclonal antibody) as first line therapy of follicular lymphoma patients with a low tumor burden: clinical and molecular evaluation. Blood 97: 101–6

    Article  PubMed  CAS  Google Scholar 

  68. Czuczman MS, Grillolopez AJ, White CA et al. (1999) Treatment of patients with lowgrade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17: 268–76

    PubMed  CAS  Google Scholar 

  69. Vose JM, Wahl RL, Saleh M et al. (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 18: 1316–23, 2000.

    PubMed  CAS  Google Scholar 

  70. Kaminski MS, Estes J, Zasadny KR et al. (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-hodgkin lymphoma: updated results and long-term follow-up of the university of michigan experience. Blood 96: 1259–66

    PubMed  CAS  Google Scholar 

  71. Witzig TE, White CA, Wiseman GA et al. (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 17: 3793–803

    PubMed  CAS  Google Scholar 

  72. Marcus R, Imrie K, Belch A et al. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4): 1417–23

    Article  PubMed  CAS  Google Scholar 

  73. Denham JW, Denham E, Dear KB, Hudson GV (1996) The follicular non-Hodgkin’s lymphomas. 1. The possibility of cure. Eur J Cancer 32A: 470–9

    Article  PubMed  CAS  Google Scholar 

  74. Gribben JG, Neuberg D, Freedman AS et al. (1993) Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81: 3449–57

    PubMed  CAS  Google Scholar 

  75. Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. (1998) The clinical significance of molecular response in indolent follicular lymphomas. Blood 91: 2955–60

    PubMed  CAS  Google Scholar 

  76. Soubeyran P, Hostein I, Debled M et al. (1999) Evolution of Bcl-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas. Br J Cancer 81: 860–9

    Article  PubMed  CAS  Google Scholar 

  77. Debled M, Hostein I, Astiergin T et al. (1999) Competitive polymerase chain reaction to quantify tumor cells in peripheral blood of patients with t(14;18)-bearing follicular non-Hodgkin’s lymphoma: An exploratory study in 8 patients. Int J Cancer 84: 558–61

    Article  PubMed  CAS  Google Scholar 

  78. Johnson PW, Price CG, Smith T et al. (1994) Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 12: 798–805

    PubMed  CAS  Google Scholar 

  79. Price CG, Meerabux J, Murtagh S et al. (1991) The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol 9: 1527–32

    PubMed  CAS  Google Scholar 

  80. Darby AJ, Lanham S, Soubeyran P, Johnson PWM (2005) Variability of quantitative polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicenter study. Haematologica 90: 1706–1707

    PubMed  CAS  Google Scholar 

  81. Fisher RI, Gaynor ER, Dahlberg S et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328: 1002–6

    Article  PubMed  CAS  Google Scholar 

  82. Dixon DO, Neilan B, Jones SE et al. (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 4: 295–305

    PubMed  CAS  Google Scholar 

  83. O’Connell MJ, Earle JD, Harrington DP et al. (1986) Initial chemotherapy doses for elderly patients with malignant lymphoma [letter]. J Clin Oncol 4: 1418

    PubMed  CAS  Google Scholar 

  84. Turner NJ, Haward RA, Mulley GP, Selby PJ (1999) Cancer in old age-is it inadequately investigated and treated? Br Med J 319: 309–12

    CAS  Google Scholar 

  85. Begg C, Cohen J, Ellerton J (1980) Are the elderly predisposed to toxicity from cancer chemotherapy. Cancer Clin Trials 3: 369–74

    PubMed  CAS  Google Scholar 

  86. Giovanazzi-Bannon S, Rademaker A, Lai G, Bensson III (1994) A Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol 12: 2447–52

    PubMed  CAS  Google Scholar 

  87. Bastion YB, Blay JY, Divine M et al. (1997) Elderly patients with aggressive non-Hodgkin’s lymphoma: Disease presentation, response to treatment, and survival-A groupe d’Etude des Lymphomes de l’Adulte study on 453 patients older than 69 years. J Clin Oncol 15: 2945–53

    PubMed  CAS  Google Scholar 

  88. Sonneveld P, van der Lelie H, Nieuwenhuis K et al. (1994) Phase III study of doxorubicin (CHOP) compared with mitoxantrone (CNOP) in elderly patients with intermediate/high risk non-hodgkin’s lymphoma. Blood 84(suppl 1): 384a

    Google Scholar 

  89. Egorin MJ (1993) Cancer pharmacology in the elderly. Sem Oncol 20: 43–9

    CAS  Google Scholar 

  90. Robert J, Hoerni B (1983) Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 43: 4467–9

    PubMed  CAS  Google Scholar 

  91. Tirelli U, Errante D, Vanglabbeke M et al. (1998) CHOP is the standard regimen in patients 70 years of age with intermediate-grade and high-grade non-Hodgkin’s lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16: 27–34

    PubMed  CAS  Google Scholar 

  92. Zinzani PL, Pavone E, Storti S et al. (1997) Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly highgrade non-Hodgkin’s lymphoma. Blood 89: 3974–9

    PubMed  CAS  Google Scholar 

  93. Coiffier B, Lepage E, Briere J et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346: 235–42

    Article  PubMed  CAS  Google Scholar 

  94. Osby E, Hagberg H, Kvaloy S et al. (2003) CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a ordic Lymphoma Group randomized trial. Blood 101: 3840–3848

    Article  PubMed  CAS  Google Scholar 

  95. Pfreundschuh M, Trumper L, Kloess M et al. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104(3): 634–41

    Article  PubMed  CAS  Google Scholar 

  96. Pfreundschuh M, Kloess M, Schmits R et al. (2005) Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the erman High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 106:Abstract 13

    Google Scholar 

  97. Sonneveld P, van Putten W, Holte H et al. (2005) Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized hase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups. Blood 106: Abstract 16

    Google Scholar 

  98. Meyer RM, Browman GP, Samosh ML et al. (1995) Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin’s lymphoma. J lin Oncol 13: 2386–93

    CAS  Google Scholar 

  99. Soubeyran P, Eghbali H, Ceccaldi J et al. (1998) Randomized phase II trial of two schedules including cyclophosphamide (C), epirubicin (E), etoposisde (V), vincristine (O) and rednisone (P) in intermediate and high grade non-Hodgkin’s lymphomas (IHG NHL). J Clin Oncol 17: 38a

    Google Scholar 

  100. Soubeyran P, Eghbali H, Cany L et al. (1999) Intermediate and high-grade non-hodgkin’s lymphomas in the elderly. Prospective registration study in a regional lymphoma network. Blood 94(Suppl. 1): 524a

    Google Scholar 

  101. Isaacson PG (1999) Gastric MALT lymphoma: From concept to cure. Ann Oncol 10: 637–45

    Article  PubMed  CAS  Google Scholar 

  102. Rohatiner A, D’Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem P, Shipp M et al. (1994) Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 5: 397–400

    PubMed  CAS  Google Scholar 

  103. de Boer WA, Tytgat GNJ (2000) Treatment of Helicobacter Pylori infection. Br Med J 320: 31–4

    Article  Google Scholar 

  104. Wotherspoon AC, Doglioni C, Diss TC et al. (1993) Regression of primary low-grade Bcell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342: 575–7

    Article  PubMed  CAS  Google Scholar 

  105. Neubauer A, Thiede C, Morgner A et al. (1997) Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Nat Cancer Inst 89: 1350–5

    Article  PubMed  CAS  Google Scholar 

  106. Schechter NR, Portlock CS, Yahalom J (1998) Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 16: 1916–21

    PubMed  CAS  Google Scholar 

  107. Schechter NR, Yahalom J (2000) Low-grade MALT lymphoma of the stomach: a review of treatment options. Int J Radiat Oncol Biol Phys 46: 1093–103

    Article  PubMed  CAS  Google Scholar 

  108. Hammel P, Haioun C, Chaumette MT et al. (1995) Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. Journal of Clinical Oncology 13: 2524–9

    PubMed  CAS  Google Scholar 

  109. Thieblemont C, Berger F, Dumontet C et al. (2000) Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95: 802–6, 2000.

    PubMed  CAS  Google Scholar 

  110. Nathwani BN, Anderson JR, Armitage JO et al. (1999) Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. J Clin Oncol 17: 2486–92

    PubMed  CAS  Google Scholar 

  111. Velders GA, Kluinnelemans JC, Deboer CJ et al. (1996) Mantle-cell lymphoma: A population-based clinical study. J Clin Oncol 14: 1269–74

    PubMed  CAS  Google Scholar 

  112. Coiffier B (1998) Which treatment for mantle-cell lymphoma patients in 1998? J Clin Oncol 16: 3–5

    PubMed  CAS  Google Scholar 

  113. Meusers P, Engelhard M, Bartels H et al. (1989) Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 7: 365–80

    Article  PubMed  CAS  Google Scholar 

  114. Foran JM, Rohatiner AZS, Coiffier B et al. (1999) Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom’s macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17: 546–53

    PubMed  CAS  Google Scholar 

  115. Decaudin D, Bosq J, Tertian G et al. (1998) Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 16: 579–83

    PubMed  CAS  Google Scholar 

  116. Zinzani PL, Magagnoli M, Moretti L et al. (2000) Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 18: 773–9

    PubMed  CAS  Google Scholar 

  117. Coiffier B, Haioun C, Ketterer N et al. (1998) Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study. Blood 92: 1927–32

    PubMed  CAS  Google Scholar 

  118. Foran JM, Cunningham D, Coiffier B et al. (2000) Treatment of mantle-cell lymphoma with Rituximab (Chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response. Ann Oncol 11: 117–21, 2000.

    Article  PubMed  Google Scholar 

  119. Campo E, Gaulard P, Zucca E et al. (1998) Report of the European task force on lymphomas: Workshop on peripheral T-cell lymphomas. Ann Oncol 9: 835–43

    Article  PubMed  CAS  Google Scholar 

  120. Lopez-Guillermo A, Cid J, Salar A et al. (1998) Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL Classification. Ann Oncol 9: 849–55

    Article  PubMed  CAS  Google Scholar 

  121. Gisselbrecht C, Gaulard P, Lepage E et al. (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Blood 92: 76–82

    PubMed  CAS  Google Scholar 

  122. Ansell SM, Habermann TM, Kurtin PJ et al. (1997) Predictive capacity of the international prognostic factor index in patients with peripheral T-cell lymphoma. J Clin Oncol 15: 2296–301

    PubMed  CAS  Google Scholar 

  123. Cheng AL, Su IJ, Chen CC et al. (1994) Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study. J Clin Oncol 12: 1185–92

    PubMed  CAS  Google Scholar 

  124. Zinzani PL, Magagnoli M, Bendandi M et al. (1998) Therapy with Gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9: 1351–3

    Article  PubMed  CAS  Google Scholar 

  125. Cheson BD, Bennett JM, Grever M et al. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990–7

    PubMed  CAS  Google Scholar 

  126. Chronic lymphocytic leukemia (1989) recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med 110: 236–8

    Google Scholar 

  127. Catovsky D, Richards S, Fooks J (1991) CLL trials in the United Kingdom. Leuk Lymphoma 5(Suppl.): 105–12

    Article  Google Scholar 

  128. Spanish Cooperative Group on CLL (1991) Treatment of chronic lymphocytic leukemia: a preliminary report of Spanish (PETHEMA) trials. Leuk Lymphoma 5(Suppl.): 89–91

    Google Scholar 

  129. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A) (1990) results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 75: 1414–21

    Google Scholar 

  130. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial (1993) The French Cooperative Group on Chronic Lymphocytic Leukemia. Semin Oncol 20: 21–3

    Google Scholar 

  131. Fabbri A, Lenoci M, Gozzetti A et al. (2004) Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. Hematol J 5: 472–4

    Article  PubMed  CAS  Google Scholar 

  132. Keating MJ, O’Brien S, Albitar M et al. (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23: 4079–88

    Article  PubMed  CAS  Google Scholar 

  133. Elter T, Borchmann P, Schulz H et al. (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23: 7024–31

    Article  PubMed  CAS  Google Scholar 

  134. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia (1988) A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med 319: 902–7

    Google Scholar 

  135. Alexanian R, Dimopoulos M. (1994) The treatment of multiple myeloma. N Engl J Med 330: 484–9

    Article  PubMed  CAS  Google Scholar 

  136. Bataille R, Harousseau JL (1997) Multiple myeloma. N Engl J Med 336: 1657–64

    Article  PubMed  CAS  Google Scholar 

  137. Berenson JR, Lichtenstein A, Porter L et al. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488–93

    Article  PubMed  CAS  Google Scholar 

  138. Blade J, Munoz M, Fontanillas M et al. (1996) Treatment of multiple myeloma in elderly people: long-term results in 178 patients. Age Ageing 25: 357–61

    Article  PubMed  CAS  Google Scholar 

  139. Gregory WM, Richards MA, Malpas JS (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10: 334–42

    PubMed  CAS  Google Scholar 

  140. Mandelli F, Avvisati G, Amadori S et al. (1990) Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322: 1430–4

    Article  PubMed  CAS  Google Scholar 

  141. Salmon SE, Crowley JJ, Grogan TM et al. (1994) Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 12: 2405–14

    PubMed  CAS  Google Scholar 

  142. Westin J, Rodjer S, Turesson I et al. (1995) Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group. Br J Haematol 89: 561–8

    PubMed  CAS  Google Scholar 

  143. Browman GP, Bergsagel D, Sicheri D et al. (1995) Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 13: 2354–60

    PubMed  CAS  Google Scholar 

  144. Peest D, Deicher H, Coldewey R et al. (1995) A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 31A: 146–51

    Article  PubMed  CAS  Google Scholar 

  145. Ludwig H, Cohen AM, Polliack A et al. (1995) Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 6: 467–76

    PubMed  CAS  Google Scholar 

  146. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma (1996) A randomized, controlled trial. The Nordic Myeloma Study Group. Ann Intern Med 124: 212–22

    Google Scholar 

  147. Wisloff F, Hjorth M, Kaasa S, Westin J (1996) Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br J Haematol 94: 324–32

    Article  PubMed  CAS  Google Scholar 

  148. Hideshima T, Chauhan D, Shima Y et al. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943–50

    PubMed  CAS  Google Scholar 

  149. Raje N, Anderson K (1999) Thalidomide—a revival story [editorial; comment]. N Engl J Med 341: 1606–9

    Article  PubMed  CAS  Google Scholar 

  150. Rajkumar SV, Blood E, Vesole D et al. (2005) Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol Dec 19 [Epub ahead of print]

    Google Scholar 

  151. Ludwig H, Drach J, Tóthová E et al. (2005) Thalidomide-Dexamethasone Versus Melphalan-Prednisolone as First Line Treatment in Elderly Patients with Multiple Myeloma: An Interim Analysis. Blood 2005 106: Abstract 782

    Google Scholar 

  152. Dimopoulos MA, Spencer A, Attal M et al. (2005) Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010). Blood 106: Abstract 6

    Article  Google Scholar 

  153. Mateos MV, Hernández M, mnDíaz Mediavilla J et al. (2005) A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma (MM) Patients. Blood. 106: Abstract 786

    Google Scholar 

  154. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group. Br J Haematol 33: 451–8, 1976.

    PubMed  CAS  Google Scholar 

  155. Bennett JM, Catovsky D, Daniel MT et al. (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103: 620–5

    PubMed  CAS  Google Scholar 

  156. Williamson PJ, Kruger AR, Reynolds PJ et al. (1994) Establishing the incidence of myelodysplastic syndrome. Br J Haematol 87: 743–5

    PubMed  CAS  Google Scholar 

  157. Oscier DG (1997) ABC of clinical haematology. The myelodysplastic syndromes. Br Med J 314: 883–6

    CAS  Google Scholar 

  158. Cheson BD, Bennett JM, Kantarjian H et al. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96: 3671–4

    PubMed  CAS  Google Scholar 

  159. Lowenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341: 1051–62

    Article  PubMed  CAS  Google Scholar 

  160. Hiddemann W, Kern W, Schoch C et al. (1999) Management of acute myeloid leukemia in elderly patients. J Clin Oncol 17: 3569–76

    PubMed  CAS  Google Scholar 

  161. Leith CP, Kopecky KJ, Godwin J et al. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89: 3323–9

    PubMed  CAS  Google Scholar 

  162. de Lima M, Strom SS, Keating M et al. (1997) Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood 90: 4719–24

    PubMed  Google Scholar 

  163. Lowenberg B, Zittoun R, Kerkhofs H et al. (1989) On the value of intensive remissioninduction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7: 1268–74

    PubMed  CAS  Google Scholar 

  164. Estey EH (2000) How I treat older patients with AML. Blood 96: 1670–3

    PubMed  CAS  Google Scholar 

  165. Amadori S, Suciu S, Willemze R et al. (2004) Upfront window trial of gemtuzumab ozogamicin in previously untreated elderly patients with AML: an EORTC Leukemia Group study. Blood 104: 250a

    Article  CAS  Google Scholar 

  166. De Angelo D, Stone R, Durant S et al. (2003) Gemtuzumab ozogamicin in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: two age-specific phase II trials. Blood 102: 100a

    Google Scholar 

  167. Dombret H, Chastang C, Fenaux P et al. (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 332: 1678–83

    Article  PubMed  CAS  Google Scholar 

  168. Godwin JE, Kopecky KJ, Head DR et al. (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 91: 3607–15

    PubMed  CAS  Google Scholar 

  169. Rowe JM, Andersen JW, Mazza JJ et al. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86: 457–62

    PubMed  CAS  Google Scholar 

  170. Stone RM, Berg DT, George SL et al. (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 332: 1671–7

    Article  PubMed  CAS  Google Scholar 

  171. Witz F, Sadoun A, Perrin MC et al. (1998) A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAMS). Blood 91: 2722–30

    PubMed  CAS  Google Scholar 

  172. Lowenberg B, Suciu S, Archimbaud E et al. (1997) Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 90: 2952–61

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie médicale, Institut Bergonié, 229, cours de l’Argonne, 33076, Bordeaux Cedex

    Pierre Soubeyran & Alain Monnereau

Authors
  1. Pierre Soubeyran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alain Monnereau
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Service d’oncologie médicale, CHU Avicenne, 125, rue de Stalingrad, 93009, Bobigny Cedex

    Jean-François Morère

  2. Centre de gériatrie, Hôpital Xavier-Arnozan, Avenue du Haut-Levêque, 33604, Pessac

    Muriel Rainfray

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France

About this chapter

Cite this chapter

Soubeyran, P., Monnereau, A. (2007). Lymphomes et autres tumeurs hématologiques. In: Morère, JF., Rainfray, M. (eds) Cancer du sujet âgé. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-48618-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-48618-0_14

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25209-9

  • Online ISBN: 978-2-287-48618-0

Publish with us

Policies and ethics

Search

Navigation